Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 2Phase 1/2 2Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 24Neoplasms 11Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 8Multiple Myeloma 8Lung Neoplasms 6Melanoma 5Leukemia, Myeloid, Acute 5Neoplasm Metastasis 4Glioma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Tuberous Sclerosis 3Stomach Neoplasms 3Sarcoma 3Papillomavirus Infections 3Leiomyoma 3Hematologic Neoplasms 3Glioblastoma 3Carcinoma, Renal Cell 3Polycythemia Vera 2Pain 2Oligodendroglioma 2Neoplasms by Site 2Myasthenia Gravis 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Heart Failure 2Febrile Neutropenia 2Endometrial Neoplasms 2Bronchiolitis Obliterans Syndrome 2

Interventions

nirogacestat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Desmoid Tumors × 90 days × Clear all
NCT07176689 2026-05-08

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 4 Recruiting
50 enrolled
Sarcoma

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡